



(51) International Patent Classification:
C07K 16/08 (2006.01)

(21) International Application Number:
PCT/EP2024/079595

(22) International Filing Date:
18 October 2024 (18.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2351206-4 20 October 2023 (20.10.2023) SE

(71) Applicant: CYTIVA BIOPROCESS R&D AB [SE/SE];
Björkgatan 30, 751 84 Uppsala (SE).

(72) Inventors: JONSSON, Andreas L. M.; Scheeles Väg 3,
171 65 Solna (SE). MYHRINDER, Gustav; Scheeles Väg
3, 171 65 Solna (SE). MELIN, Ellen; Björkgatan 30, 751
84 Uppsala (SE). JÄRVER, Peter; Scheeles Väg 3, 171 65
Solna (SE). ÅSTRAND, Mikael C; Björkgatan 30, 751 84
Uppsala (SE).

(74) Agent: SPJUTH, Nora; Cytiva Sweden AB, Björkgatan
30, 751 84 Uppsala (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: AAV9 BINDING POLYPEPTIDES




Fig. 4a

(57) Abstract: The invention provides an antigen-binding polypeptide capable of binding adeno-associated virus serotype 9 (AAV9), the polypeptide comprising a single-domain antibody (sdAb) variant having complementarity determining regions CDR1, CDR2 and CDR3 as disclosed herein. The antigen-binding polypeptide is useful as an affinity ligand for affinity capture applications, such as affinity separation.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*